Island Pharmaceuticals is focused on drug repurposing to develop antiviral therapeutics aimed at combating infectious diseases, particularly those caused by viruses such as dengue. Their lead program, ISLA-101, is positioned for a rapid transition to clinical trials, leveraging existing clinical data and collaborating with institutions like the State University of New York for a Phase II Clinical Trial. This trial will utilize a human challenge model, where healthy volunteers are intentionally infected with an attenuated dengue virus to study the effects of the drug in a controlled environment. This innovative approach allows for a more efficient study design, requiring fewer participants while maintaining strict control over variables.

The company is also engaged in research collaborations to build a comprehensive antiviral drug repurposing pipeline. Their focus on infectious diseases includes understanding the mechanisms of alphaviruses and flaviviruses, which are transmitted by arthropods and can lead to significant health issues. With no specific antiviral treatments currently available for many of these infections, Island Pharmaceuticals aims to address this gap through their research and development efforts. Their commitment to advancing therapeutic options is underscored by their exploration of human challenge trials, which are seen as a promising avenue for accelerating the development of new drugs and vaccines.

Australia

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections.

We have a lead asset – ISLA-101 - that was initially developed by our wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

Island Pharmaceuticals

Company Details